48,830
edits
(→Renal medullary carcinoma: split out) |
|||
Line 278: | Line 278: | ||
*Papillary RCC type 1 vs. papillary RCC type 2: | *Papillary RCC type 1 vs. papillary RCC type 2: | ||
** E-cadherin +ve in PRCC type 2.<ref name=pmid14657952>{{cite journal |author=Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R |title=Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases |journal=Mod. Pathol. |volume=17 |issue=2 |pages=180? |year=2004 |month=February |pmid=14657952 |doi=10.1038/modpathol.3800032 |url=}}</ref> | ** E-cadherin +ve in PRCC type 2.<ref name=pmid14657952>{{cite journal |author=Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R |title=Expression of MUC1 (EMA) and E-cadherin in renal cell carcinoma: a systematic immunohistochemical analysis of 188 cases |journal=Mod. Pathol. |volume=17 |issue=2 |pages=180? |year=2004 |month=February |pmid=14657952 |doi=10.1038/modpathol.3800032 |url=}}</ref> | ||
**EMA (MUC1) +ve in PRCC type 1.<ref name=pmid14657952/> | **[[EMA]] (MUC1) +ve in PRCC type 1.<ref name=pmid14657952/> | ||
*ChRCC vs. oncocytoma (ONC): | *ChRCC vs. oncocytoma (ONC): |
edits